Get the Stockscreener App
2.27
6.20%
-0.15
Iovance Biotherapeutics Inc stock is traded at $2.27, with a volume of 8.47M.
It is down -6.20% in the last 24 hours and up +1.79% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.42
Open:
$2.42
24h Volume:
8.47M
Relative Volume:
0.56
Market Cap:
$821.41M
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-1.8455
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
-8.84%
1M Performance:
+1.79%
6M Performance:
-40.58%
1Y Performance:
-76.00%
1-Day Range:
$2.27
$2.43
1-Week Range:
$2.27
$2.48
52-Week Range:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.27 | 861.21M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Analysts - MarketBeat
Iovance Biotherapeutics, Inc. $IOVA Shares Sold by American Century Companies Inc. - MarketBeat
Jacobs Levy Equity Management Inc. Takes Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Invenomic Capital Management LP Purchases Shares of 5,489,799 Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics at H.C. Wainwright Conference: Strategic Growth and Efficiency - Investing.com Canada
Growth Review: Will Iovance Biotherapeutics Inc. stock go up in YEARRisk Management & Stepwise Swing Trade Plans - Lancaster City Council
Is Iovance Biotherapeutics Inc. Forming a Consolidation BaseMarket Activity Report & Weekly Setup with High ROI Potential - beatles.ru
Is Iovance Biotherapeutics Inc. a turnaround storyJuly 2025 Pullbacks & Fast Gaining Stock Strategy Reports - beatles.ru
H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News - Yahoo Finance
Iovance Biotherapeutics Soars as Health Canada Approves Amtagvi T Cell Therapy - StocksToTrade
Iovance Biotherapeutics Leaps Forward with Health Canada Approval - timothysykes.com
683 Capital Management LLC Boosts Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics Secures Canadian Approval for Groundbreaking Therapy - StocksToTrade
Iovance Biotherapeutics Surges After Amtagvi Approval in Canada - timothysykes.com
Iovance Biotherapeutics, Inc. $IOVA Stock Holdings Trimmed by Rafferty Asset Management LLC - MarketBeat
Is Iovance Biotherapeutics Inc. benefiting from interest rate changes2025 Biggest Moves & Growth Focused Entry Point Reports - خودرو بانک
Using Bollinger Bands to evaluate Iovance Biotherapeutics Inc.Trade Ideas & Long-Term Investment Growth Plans - Newser
What institutional flow reveals about Iovance Biotherapeutics Inc.IPO Watch & Low Risk Investment Opportunities - Newser
Using economic indicators to assess Iovance Biotherapeutics Inc. potentialWeekly Trade Review & Real-Time Volume Analysis - Newser
Iovance Biotherapeutics at Wells Fargo Conference: Strategic Moves and Challenges - Investing.com Canada
Is this a good reentry point in Iovance Biotherapeutics Inc.Weekly Investment Report & Low Drawdown Momentum Ideas - Newser
Should I add Iovance Biotherapeutics Inc. stock to my portfolio2025 Technical Patterns & Weekly Stock Performance Updates - خودرو بانک
How to use a screener to detect Iovance Biotherapeutics Inc. breakoutsTrade Analysis Summary & Safe Entry Trade Reports - Newser
Multi factor analysis applied to Iovance Biotherapeutics Inc.Weekly Investment Summary & AI Powered Trade Plan Recommendations - Newser
How to read the order book for Iovance Biotherapeutics Inc.July 2025 Spike Watch & Real-Time Stock Entry Alerts - Newser
Chart based analysis of Iovance Biotherapeutics Inc. trendsNew Guidance & Breakout Confirmation Trade Signals - Newser
Tools to monitor Iovance Biotherapeutics Inc. recovery probabilityEarnings Beat & AI Enhanced Trading Alerts - Newser
Iovance Biotherapeutics, Inc. $IOVA Shares Acquired by Long Focus Capital Management LLC - MarketBeat
Is Iovance Biotherapeutics Inc. forming a bottoming baseJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - Newser
Does Iovance Biotherapeutics Inc. qualify in momentum factor screeningAnalyst Upgrade & Safe Investment Capital Preservation Plans - Newser
Key resistance and support levels for Iovance Biotherapeutics Inc.Trade Analysis Report & Weekly Momentum Picks - Newser
Reversal indicators forming on Iovance Biotherapeutics Inc. stockTrade Risk Summary & Consistent Return Strategy Ideas - Newser
Artisan Small Cap Fund Exited Its Stake in Iovance Biotherapeutics (IOVA) Due to Operational Challenges - MSN
Short Term Charts Align With Long Term Uptrend in Iovance Biotherapeutics Inc.July 2025 Recap & Free Weekly Watchlist of Top Performers - beatles.ru
Is Iovance Biotherapeutics Inc. forming a bullish divergenceWeekly Trend Recap & Weekly Watchlist for Hot Stocks - خودرو بانک
Risk adjusted return profile for Iovance Biotherapeutics Inc. analyzedQuarterly Market Summary & Daily Oversold Stock Bounce Ideas - Newser
Iovance Biotherapeutics shares rise 1.32% premarket after Immunome's presentation at H.C. Wainwright conference. - AInvest
Can machine learning forecast Iovance Biotherapeutics Inc. recovery2025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - Newser
Multi asset correlation models including Iovance Biotherapeutics Inc.July 2025 Trends & Momentum Based Trading Ideas - Newser
How to recover losses in Iovance Biotherapeutics Inc. stockMarket Volume Summary & Safe Capital Growth Trade Ideas - Newser
Custom watchlist performance reports with Iovance Biotherapeutics Inc.Weekly Trend Report & Intraday High Probability Setup Alerts - Newser
Nuveen LLC Buys Shares of 886,738 Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Chart overlay techniques for tracking Iovance Biotherapeutics Inc.Earnings Recap Summary & High Conviction Buy Zone Picks - Newser
Is Iovance Biotherapeutics Inc. stock bottoming outPortfolio Risk Summary & Long-Term Safe Investment Plans - Newser
Charles Schwab Investment Management Inc. Sells 141,599 Shares of Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Valuation Update: Is Iovance Biotherapeutics Inc. benefiting from interest rate changesMarket Performance Summary & Risk Controlled Stock Pick Alerts - خودرو بانک
What to expect from Iovance Biotherapeutics Inc. in the next 30 daysMarket Risk Report & Long-Term Growth Stock Strategies - Newser
Published on: 2025-09-01 23:03:51 - Newser
Real time social sentiment graph for Iovance Biotherapeutics Inc.Market Rally & Safe Entry Trade Reports - Newser
Building trade automation scripts for Iovance Biotherapeutics Inc.2025 Trading Recap & Daily Profit Maximizing Tips - Newser
Will Iovance Biotherapeutics Inc. bounce back from current supportMarket Performance Report & Fast Moving Stock Watchlists - Newser
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):